Liraglutide (GLP-1 RA) significantly reduced the incidence of primary endpoint: CV death, nonfatal MI and nonfatal stroke death and overall mortality. There was a lower incidence of nephropathy and a non-significantly higher incidence of retinopathy in the liraglutide group. The gene discussed is GLP1R; the disease is stroke disorder.